C
Cristina Suarez
Researcher at Autonomous University of Barcelona
Publications - 101
Citations - 4401
Cristina Suarez is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Sunitinib & Atezolizumab. The author has an hindex of 22, co-authored 95 publications receiving 2757 citations. Previous affiliations of Cristina Suarez include Hebron University & Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott,Mahrukh Huseni,Michael B. Atkins,Robert J. Motzer,Brian I. Rini,Bernard Escudier,Lawrence Fong,Richard W. Joseph,Sumanta K. Pal,James A. Reeves,Mario Sznol,John D. Hainsworth,W. Kimryn Rathmell,Walter M. Stadler,Thomas E. Hutson,Martin Gore,Alain Ravaud,Sergio Bracarda,Cristina Suarez,Riccardo Danielli,Viktor Gruenwald,Toni K. Choueiri,Dorothee Nickles,Suchit Jhunjhunwala,Elisabeth Piault-Louis,Alpa Thobhani,Jiaheng Qiu,Daniel S. Chen,Priti S. Hegde,Christina Schiff,Gregg Fine,Thomas Powles +31 more
TL;DR: Molecular profiles suggest that prediction of outcomes with anti-VEGF and immunotherapy may be possible and offer mechanistic insights into how blocking VEGF may overcome resistance to immune checkpoint blockade.
Journal ArticleDOI
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini,Thomas Powles,Michael B. Atkins,Bernard Escudier,David F. McDermott,Cristina Suarez,Sergio Bracarda,Walter M. Stadler,Frede Donskov,Jae-Lyun Lee,Robert E. Hawkins,Alain Ravaud,Boris Alekseev,Michael Staehler,Motohide Uemura,Ugo De Giorgi,Begoña Mellado,Camillo Porta,Bohuslav Melichar,Howard Gurney,Jens Bedke,Toni K. Choueiri,Francis Parnis,Tarik Khaznadar,Alpa Thobhani,S. Li,Elisabeth Piault-Louis,Gretchen Frantz,Mahrukh Huseni,Christina Schiff,Marjorie C. Green,Robert J. Motzer +31 more
TL;DR: Results of IMmotion151 support atezolizumab plus bevacIZumab as a first-line treatment option for selected patients with advanced renal cell carcinoma and showed a favourable safety profile.
Journal ArticleDOI
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Thomas Powles,Mark M. Kockx,Alejo Rodriguez-Vida,Ignacio Duran,Simon J. Crabb,Michiel S. van der Heijden,Bernadett Szabados,Albert Font Pous,Gwenaelle Gravis,Urbano Anido Herranz,Andrew Protheroe,Alain Ravaud,Denis Maillet,Maria Jose Mendez,Cristina Suarez,Mark Linch,Aaron Prendergast,Peter A. van Dam,Diana Stanoeva,Sofie Daelemans,Sanjeev Mariathasan,Joy S. Tea,Kelly Mousa,Romain Banchereau,Daniel Castellano +24 more
TL;DR: A single-arm multicenter phase 2 trial demonstrates clinical efficacy of neoadjuvant PD-L1 blockade in patients with resectable muscle-invasive bladder cancer ineligible for cisplatin and examines biomarkers associated with patient outcome.
Journal ArticleDOI
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Thomas Powles,Michiel S. van der Heijden,Daniel Castellano,Matthew D. Galsky,Yohann Loriot,Daniel P. Petrylak,Osamu Ogawa,Se Hoon Park,Jae-Lyun Lee,Ugo De Giorgi,Martin Bögemann,Aristotelis Bamias,Bernhard J. Eigl,Howard Gurney,Som D. Mukherjee,Yves Fradet,Iwona Skoneczna,Marinos Tsiatas,Andrey Novikov,Cristina Suarez,Andre P. Fay,Ignacio Duran,Andrea Necchi,Sophie Wildsmith,Philip He,Natasha Angra,Ashok K. Gupta,Wendy Levin,Joaquim Bellmunt,Jae-Lyun Lee,Hans Westgeest,Aude Flechon,Yen-Chuan Ou,Inkeun Park,Vsevolod Matveev,Begoña Perez-Valderrama,Susanna Cheng,Stephen Jay Frank,Urbano Anido,Alketa Hamzaj,Margitta Retz,Srikala S. Sridhar,Giorgio V. Scagliotti,Jens Voortman,Boris Alekseev,Anna Alyasova,Boris Komyakov,Herlinde Dumez,Michel Pavic,Go Kimura,Atsushi Mizokami,Susanne Osanto,Jose Angel Arranz,Djura Piersma,Sang Joon Shin,Oleg Karyakin,Ignacio Delgado,Jose Luis Gonzalez,See-Tong Pang,Anna Tran,Oleg Lipatov,Wen Pin Su,Thomas W. Flaig,Ajjai Alva,Hwa Park Kyong,Evgeny Kopyltsov,Elena Almagro,Monserrat Domenech,Yen-Hwa Chang,Brieuc Sautois,Andre Ravaux,Gerasimos Aravantinos,Vasileios Georgoulias,Sasja Mulder,Yu Jung Kim,Fabio Kater,Christine Chevreau,Scott T. Tagawa,Pawel Zalewski,Florence Joly,Gencay Hatiboglu,Luca Gianni,Franco Morelli,Rosa Tambaro,Yasuhiro Hashimoto,Alexander Nosov,Albert Font,Alejo Rodriguez-Vida,Robert Jones,Naveen S. Vasudev,Sandhya Srinivas,Jingsong Zhang,Thierry Gil,Daygen Finch,Marc-Oliver Grimm,Yu-Li Su,Simon Chowdhury,Christopher Hocking,Eugen Plas,Scott North,Niels Viggo Jensen,Christine Theodore,Florian Imkamp,Avivit Peer,Takashi Kobayashi,Hideki Sakai,Naoto Sassa,Kazuhiro Yoshimura,Maureen J.B. Aarts,Ana Ferreira Castro,Marlen Topuzov,Juan Francisco Rodriguez,Federico Vazquez,Yu-Chieh Tsai,Simon J. Crabb,Syed A. Hussain,Johanna C. Bendell,Marine Gross-Goupil,Gravis Gwenaelle,Raanan Berger,Galina Statsenko,Linda Evans,Alexandra Drakaki,Bradley Somer,Ian D. Davis,James Lynam,Giuliano Santos Borges,Aldo Dettino,Graziella Martins,Luis Eduardo Zucca,Mads Agerbæk,Haralambos Kalofonos,Eli Rosenbaum,Hideki Enokida,Hiroaki Kikukawa,Kazuo Nishimura,Satoshi Tamada,Motohide Uemura,Yamil Lopez,Jourik A. Gietema,Marcin Slojewski,Isabel Fernandes,Alexey Smolin,Danish Mazhar,Arash Rezazadeh Kalebasty,Bradley Carthon,Wolfgang Loidl,Fabio Franke,Gustavo Girotto,Nimira S. Alimohamed,Robyn Macfarlane,Helle Pappot,Guenter Niegisch,Dimitrios Mavroudis,Avishay Sella,Camillo Porta,Shin Ebara,Motonobu Nakamura,Wataru Obara,Norihiko Okuno,Nobuo Shinohara,Mikio Sugimoto,Akitaka Suzuki,Noriaki Tokuda,Hiroji Uemura,Akito Yamaguchi,Francisco Ramirez,Pawel Rozanowski,Paweł Wiechno,Bhumsuk Keam,Nikolay Kislov,Denis Plaksin,Irfan Cicin,Satish Kumar,Joseph Rosales,Ulka N. Vaishampayan,Stéphane Culine,Christos Papandreou,Taketoshi Nara,Mustafa Erman,Laurence Kreiger,Juliana Janoski,Diogo Rosa,Mariana Siqueira,Christina Canil,Lisa Sengeløv,Jean-Marc Tourani,Gaku Arai,Katsuyoshi Hashine,Mutsushi Kawakita,Noboru Nakaigawa,Hayahito Nomi,Hiroaki Shiina,Hiroyoshi Suzuki,Junji Yonese,Roberto Kuri,Eleazar Macedo,Samuel Rivera,Alberto Villalobos Prieto,Anna Polakiewicz-Gilowska,Renata Zaucha,Fabio Lopes,Roman Ponomarev,Mark Pomerantz,Shahrokh F. Shariat,Cynthia Luk,Krzysztof Lesniewski-Kmak +206 more
TL;DR: The overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab ( a CTLA-4 inhibitor), as a first-line treatment for metastatic urothelial carcinoma was assessed.
Journal ArticleDOI
IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
Robert J. Motzer,Thomas Powles,Michael B. Atkins,Bernard Escudier,David F. McDermott,Cristina Suarez,Sergio Bracarda,Walter M. Stadler,Frede Donskov,Jae-Lyun Lee,Robert E. Hawkins,Alain Ravaud,Boris Alekseev,Michael Staehler,Motohide Uemura,Francis Donaldson,S. Li,Mahrukh Huseni,Christina Schiff,Brian I. Rini +19 more
TL;DR: The first randomized Phase III trial of a PD-L1/PD-1 pathway inhibitor combined with an anti-VEGF agent in 1L mRCC is described.